Infant Cancer Survival Rates Lag Behind Older Children Due to Treatment Toxicity
Infants diagnosed with cancer face a distinct survival disadvantage compared with older children, driven primarily by treatment-related mortality rather than more aggressive disease or higher relapse rates, ajmc.com reported. Of 53 infants who died during follow-up in a recent study, 22.6% succumbed to treatment toxicities or other complications. Deaths from treatment toxicity occurred in 4.8% of infants compared with just 1.5% of older children, yielding a hazard ratio of 4.03.
This mortality gap widened despite grade 3 and 4 treatment-related complications being reported at comparable rates between the two groups, at 13.7% for infants and 14.9% for older children. Overall survival in infants lagged significantly behind at 1 year, with rates of 63.7% compared with 81.5% for older patients. By 5 years, overall survival for infants stood at 56.9%, trailing the 62.0% observed in older children, with infant deaths tending to occur earlier in the course of care.
Relapse Rates and Disease Aggressiveness in Pediatric Cancer
Disease relapse by 5 years was actually less common among infants, affecting 26.3% of the group compared with 38.4% of older children, though this difference did not reach statistical significance. Study authors noted that the survival disadvantage in infants stems from excess treatment-related toxicity. Infants process drugs differently than older pediatric patients, a physiological variation that can render a toxicity of a given grade far more dangerous during the first year of life.
Outcomes varied wildly depending on the specific tumor type. Survival at 5 years for infants was lowest with malignant rhabdoid tumors at 16.8%, while infantile fibrosarcoma yielded the highest survival rate at 92.7%. Therapeutic approaches have shifted for specific subsets, as the FDA has approved larotrectinib for solid tumors harboring NTRK gene fusions, transforming management for NTRK fusion-positive infantile fibrosarcoma.
Clinical Trial Exclusion and the Path Forward for Age-Adapted Pediatric Care
Early-phase trials for targeted therapies have historically left infants behind. Early-phase trials of the EZH2 inhibitor tazemetostat explicitly excluded infants younger than 1 year. Infants in the study cohort were significantly less likely than older children to be enrolled in a clinical trial, with enrollment rates of 8.4% versus 19.8%.
The retrospective design of the study introduced limitations, including potential data incompleteness or misclassification, while the rarity of individual cancer subtypes reduced statistical power for subgroup comparisons. Routine capture of molecular data was lacking, and researchers could not definitively identify the specific therapy responsible for each individual treatment-related death. Future progress requires biologically informed diagnostics, risk stratification, age-adapted therapeutic drug monitoring, and the expansion of age limits in early-phase trials to include infants.
Frequently Asked Questions About Infant Cancer Survival and Treatment Toxicity
Why do infants experience higher rates of treatment-related mortality than older children?
Infants process medications differently than older pediatric patients, which makes standard treatment toxicities significantly more dangerous during the first year of life. Although severe complications occurred at similar rates across age groups, the physiological vulnerability of infants contributed to a treatment-related mortality rate of 4.8% compared with 1.5% in older children.
How do survival rates differ across specific infant cancer subtypes?
Prognosis varies dramatically by diagnosis, with 5-year survival reaching 92.7% for infants with fibrosarcoma. Conversely, infants diagnosed with malignant rhabdoid tumors face the lowest 5-year survival rate at 16.8%.
What barriers do infants face regarding clinical trial access?
Infants are less than half as likely to be enrolled in clinical trials compared with older children, with enrollment rates standing at 8.4% and 19.8% respectively. Early-phase trials of the EZH2 inhibitor tazemetostat have excluded infants younger than 1 year.
Related reading